Dr Yuan on Dual-Pathway Targeted Strategies in ER+/HER2+ Breast Cancer

Yuan Yuan, MD, PhD, discusses T-DXd plus pertuzumab in first-line HER2-positive advanced/metastatic breast cancer.

Yuan Yuan, MD, PhD, reports the intracranial efficacy of T-DXd plus pertuzumab in HER2-positive breast cancer, per results from the DESTINY-Breast12 study.

Yuan Yuan, MD, PhD, discusses the importance of optimizing dual-pathway targeting in ER-positive, HER2-positive metastatic disease.

Yuan Yuan, MD, PhD, discusses a new treatment approach involving induction T-DXd followed by trastuzumab/pertuzumab maintenance in HER2-positive disease.

Yuan Yuan, MD, PhD, discusses questions regarding the potential benefit of T-DXd in first line regimens for HER2-positive breast cancer with CNS metastases.

Yuan Yuan, MD, PhD, discussed the evolving landscape of therapeutic targets and payloads for ADCs in HER2-positive breast cancer.